R94.3 F00-F99
Conditions
Interventions
Group 1: Intervention group: Guideline-based monitoring of QTc time supported by a clinical pharmacist who may order ECG and laboratory checks
Group 2: Control group: Guideline-based monitoring of QTc
Sponsors
Zentrum für Integrative Psychiatrie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Admission to wards B3.01, B3.11, B6.01 and to the day clinic B22 - Expected length of stay at least 30 days - Use of at least one QT-prolonging drug during the stay (known, possible or conditional risk according to CredibleMeds) - Signed declaration of consent
Exclusion criteria
Exclusion criteria: - Patients who are not taking a QT-prolonging drug during the study period - Patients who sleep on the psychiatric wards but who are hospitalized for somatic treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in QTc time in the observation period between T0 (QTc time in ECG on admission) and T1 (QTc time in ECG 30 days after admission) The QT time for heart rates 70/min using the Fridericia formula. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Number of patients with QTc prolongation o QTc times > 450 ms (m) or > 460 ms (f) o or > 500 ms o or increase of > 60 ms - Implementation rate of guideline recommendations - Occurrence of cardiac events - Satisfaction of psychiatric physicians with the pharmaceutical support - Physicians' desire for continuation of pharmaceutical support | — |
Countries
Germany
Contacts
Public ContactKatharina Wien
Universitätsklinikum Schleswig-Holstein, Apotheke
Outcome results
None listed